## FORM 6-K

# SECURITIES AND EXCHANGE COMMISSION <br> Washington D.C. 20549 

## Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending September 2009

## GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

[^0]
# Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K 

Securities Exchange Act of 1934.

## Yes No x

--

## Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of the change in interests in the Ordinary shares of GlaxoSmithKline plc in respect of the under-mentioned person:

Ms C Thomas exercised an award over 4,421 Ordinary shares under the Company's Annual Incentive Plan on 28 August 2009 and sold 1,806 at a price of $£ 12.17$ per share on 1 September to meet the tax liability arising from this exercise.

The Company and the above named individual were advised of this transaction on 1 September 2009.
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bickell
Company Secretary
1 September 2009

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline ple
(Registrant)

Date: September 1, 2009

## By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on behalf of GlaxoSmithKline plc


[^0]:    Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the

